{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T08:48:28Z","timestamp":1782031708184,"version":"3.54.5"},"reference-count":21,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009812","name":"Princess Margaret Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009812","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018729","name":"Materials and Energy Research Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018729","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100032415","name":"Peter Munk Cardiac Centre, University Health Network","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100032415","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ijrobp.2025.12.070","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T16:14:13Z","timestamp":1768493653000},"page":"348-357","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Health-Related Quality of Life After SBRT for Oligoprogressive Disease: Results From a Phase II Prospective Trial"],"prefix":"10.1016","volume":"125","author":[{"given":"Joelle","family":"Helou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Glicksman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Bezjak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivas","family":"Raman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura A.","family":"Dawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Hope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Hosni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Javor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Lindsay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang Y.","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisling","family":"Barry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2025.12.070_bib0001","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","volume":"13","author":"Hellman","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.070_bib0002","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20160251","article-title":"Stereotactic body radiotherapy for oligoprogressive cancer","volume":"89","author":"Cheung","year":"2016","journal-title":"Br J Radiol"},{"key":"10.1016\/j.ijrobp.2025.12.070_bib0003","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1113205","article-title":"Intratumor heterogeneity and branched evolution revealed by multiregion sequencing","volume":"366","author":"Gerlinger","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2025.12.070_bib0004","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.ijrobp.2013.11.010","article-title":"Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib","volume":"88","author":"Gan","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.12.070_bib0005","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/JCO.2012.47.7455","article-title":"Ablation of a site of progression with stereotactic body radiation therapy extends sunitinib treatment from 14 to 22 months","volume":"31","author":"Straka","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.070_bib0006","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.3892\/ol.2016.5540","article-title":"Stereotactic body radiation therapy for oligoprogression of metastatic disease from gastrointestinal cancers: A novel approach to extend chemotherapy efficacy","volume":"13","author":"Wray","year":"2017","journal-title":"Oncol Lett"},{"key":"10.1016\/j.ijrobp.2025.12.070_bib0007","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0140-6736(23)01857-3","volume":"403","author":"Tsai","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2025.12.070_bib0008","article-title":"Stereotactic ablative body radiotherapy for oligoprogressive estrogen receptor\u2013positive breast cancer (TROG 20.03","volume":"2","author":"David","year":"2025","journal-title":"JCO Oncol Adv"},{"key":"10.1016\/j.ijrobp.2025.12.070_bib0009","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ijrobp.2024.08.031","article-title":"Stereotactic ablative radiation for oligoprogressive cancers: Results of the randomized phase 2 STOP trial","volume":"121","author":"Schellenberg","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.12.070_bib0010","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ijrobp.2024.09.002","article-title":"The role of stereotactic body radiotherapy in oligoprogressive malignant disease (RADIANT ): Oncologic outcomes from a phase 2 nonrandomized controlled trial","volume":"121","author":"Glicksman","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.12.070_bib0011","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ijrobp.2025.12.070_bib0012","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.jclinepi.2013.03.017","article-title":"Multiple imputation of missing values was not necessary before performing a longitudinal mixed-model analysis","volume":"66","author":"Twisk","year":"2013","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ijrobp.2025.12.070_bib0013","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jclinepi.2022.08.016","article-title":"Handling missing data in clinical research","volume":"151","author":"Heymans","year":"2022","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ijrobp.2025.12.070_bib0014","series-title":"EORTC QLQ-C30 Scoring Manual","author":"Fayers","year":"2001"},{"key":"10.1016\/j.ijrobp.2025.12.070_bib0015","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1001\/jama.2022.9265","article-title":"Effect of electronic symptom monitoring on patient-reported outcomes among patients with metastatic cancer","volume":"327","author":"Basch","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.ijrobp.2025.12.070_bib0016","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1016\/S1470-2045(19)30790-9","article-title":"International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: Recommendations of the SISAQOL Consortium","volume":"21","author":"Coens","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.070_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110505","article-title":"Stereotactic ablative radiotherapy for oligoprogressive solid tumours: A systematic review and meta-analysis","volume":"200","author":"Tan","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.070_bib0018","doi-asserted-by":"crossref","first-page":"e166","DOI":"10.1016\/j.ijrobp.2021.07.645","article-title":"Quality of life outcomes following stereotactic body radiotherapy in patients with oligo-metastatic disease: A systematic review and meta-analysis","volume":"111","author":"Barry","year":"2021","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2025.12.070_bib0019","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/BF00439229","article-title":"The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30","volume":"5","author":"King","year":"1996","journal-title":"Qual Life Res"},{"key":"10.1016\/j.ijrobp.2025.12.070_bib0020","series-title":"Guidelines for Assessing Quality of Life in EORTC Clinical Trials","author":"Rewards","year":"2002"},{"key":"10.1016\/j.ijrobp.2025.12.070_bib0021","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1111\/j.1553-2712.2007.tb01855.x","article-title":"Advanced statistics: Missing data in clinical research-part 1: An introduction and conceptual framework","volume":"14","author":"Haukoos","year":"2007","journal-title":"Acad Emerg Med"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301626000660?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301626000660?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T08:30:46Z","timestamp":1782030646000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301626000660"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0360301626000660"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.12.070","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Health-Related Quality of Life After SBRT for Oligoprogressive Disease: Results From a Phase II Prospective Trial","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.12.070","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}